Two licensing deals for Calypte
This article was originally published in Clinica
Executive Summary
Calypte Biomedical has announced two new licensing agreements. In the first, it has acquired a non-exclusive licence to patents relating to HIV-2 patents from Bio-Rad Laboratories. The licence will enable the company to expand its offering in HIV rapid testing, and sell its test globally.